knowledge -WSS

knowledge

author：focus 2025-09-30 00:39:11 - browse：942

Erik Tokat -- biotech JPM coverage from STAT — Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

“I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Latest bird flu infection made farmworker sicker than earlier cases

focus

WSS

Medicare Advantage beneficiaries sue Humana over algorithm use

Akili, maker of video game for ADHD, to be acquired for 34 million

Medicare Advantage beneficiaries sue Humana over algorithm use

Focused ultrasound for uterine fibroids: an uphill battle

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Dark money group runs ads on China biotech bill

focus

knowledge

knowledge

Tori Bowie and the unacceptable rates of Black maternal death

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Jerome Adams on the need for new antivirals for Covid

SNAP should offer more nutrition education

DIEP, the 'gold standard' of breast reconstruction, is under threat

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

What does generative AI mean for health care? We asked experts

Biohaven protein

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Lab trade group sues FDA to halt regulation of lab

leisure time

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Violet CEO on training clinicians to promote more inclusive care

Editas, Vertex strike deal on CRISPR

Medicare drug price negotiation hasn't dried up venture capital

Childbirth

Adam's Biotech Scorecard: Do Sarepta's exon

explore

focus

leisure time

entertainment